title: Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
abstract: The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours in dogs. Cases in which toceranib was used to treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)], 11/23 OSAs (1 PR and 10 SD), 12/15 thyroid carcinomas (4 PR and 8 SD), 7/8 head and neck carcinomas [1 complete response (CR), 5 PR and 1 SD] and 5/7 (1 CR and 4 SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg kg(-1) , 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74.6%) were treated 4 months or longer. Although these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours, future prospective studies are necessary to define its true activity.
authors.affiliation: Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA. cheryl.london@cvm.osu.edu
authors.forename: C
authors.initials: C
authors.lastname: London
authors.forename: T
authors.initials: T
authors.lastname: Mathie
authors.forename: N
authors.initials: N
authors.lastname: Stingle
authors.forename: C
authors.initials: C
authors.lastname: Clifford
authors.forename: S
authors.initials: S
authors.lastname: Haney
authors.forename: M K
authors.initials: MK
authors.lastname: Klein
authors.forename: L
authors.initials: L
authors.lastname: Beaver
authors.forename: K
authors.initials: K
authors.lastname: Vickery
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.forename: B
authors.initials: B
authors.lastname: Hershey
authors.forename: S
authors.initials: S
authors.lastname: Ettinger
authors.forename: A
authors.initials: A
authors.lastname: Vaughan
authors.forename: F
authors.initials: F
authors.lastname: Alvarez
authors.forename: L
authors.initials: L
authors.lastname: Hillman
authors.forename: M
authors.initials: M
authors.lastname: Kiselow
authors.forename: D
authors.initials: D
authors.lastname: Thamm
authors.forename: M L
authors.initials: ML
authors.lastname: Higginbotham
authors.forename: M
authors.initials: M
authors.lastname: Gauthier
authors.forename: E
authors.initials: E
authors.lastname: Krick
authors.forename: B
authors.initials: B
authors.lastname: Phillips
authors.forename: T
authors.initials: T
authors.lastname: Ladue
authors.forename: P
authors.initials: P
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Bryan
authors.forename: V
authors.initials: V
authors.lastname: Gill
authors.forename: A
authors.initials: A
authors.lastname: Novasad
authors.forename: L
authors.initials: L
authors.lastname: Fulton
authors.forename: J
authors.initials: J
authors.lastname: Carreras
authors.forename: C
authors.initials: C
authors.lastname: McNeill
authors.forename: C
authors.initials: C
authors.lastname: Henry
authors.forename: S
authors.initials: S
authors.lastname: Gillings
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000662:veterinary; D000694:Anal Gland Neoplasms / Q000188:drug therapy; D000695:Anal Sacs; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001050:Apocrine Glands; D001859:Bone Neoplasms / Q000188:drug therapy / Q000662:veterinary; D002277:Carcinoma / Q000188:drug therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000662:veterinary; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D009669:Nose Neoplasms / Q000188:drug therapy / Q000662:veterinary; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000662:veterinary; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000662:veterinary
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; C464577:toceranib phosphate; D020794:Receptor Protein-Tyrosine Kinases